Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tempest Therapeutics, Inc. (TPST : NSDQ)

• Company Description    Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $1.86 Daily Weekly Monthly 20 Day Moving Average: 143,103 shares Shares Outstanding: 14.81 (millions) Market Capitalization: $27.54 (millions) Beta: -1.75 52 Week High: $6.12 52 Week Low: $1.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.33% -1.71% 12 Week -18.78% -24.91% Year To Date -35.19% -42.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2000 SIERRA POINT PARKWAY SUITE 400 - BRISBANE,CA 94005 USA ph: 415-798-8589 fax: - swheeler@wheelhouselsa.com http://www.tempesttx.com

• General Corporate Information    Officers Matthew Angel - Chief Executive Officer; President and Director Stephen Brady - Chairman Nicholas Maestas - Chief Financial Officer Michael Raab - Director Christine Pellizzari - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 87978U207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 14.81 Most Recent Split Date: 4.00 (0.08:1) Beta: -1.75 Market Capitalization: $27.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 33.51 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 83.86% vs. Previous Quarter: 17.74% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -355.61 12/31/25 - -309.60 09/30/25 - -310.89 ROA 03/31/26 - -121.21 12/31/25 - -115.81 09/30/25 - -125.12 Current Ratio 03/31/26 - 0.74 12/31/25 - 2.50 09/30/25 - 2.30 Quick Ratio 03/31/26 - 0.74 12/31/25 - 2.50 09/30/25 - 2.30 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.06 12/31/25 - 1.35 09/30/25 - 1.43 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©